Psychiatry and Clinical Psychopharmacology
Case Report

Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report


Faculty of Arts and Science, Haliç University, İstanbul, Turkey

Psychiatry and Clinical Psychopharmacology 2018; 28: 107-109
DOI: 10.1080/24750573.2017.1387403
Read: 988 Downloads: 446 Published: 09 February 2021

Irritable bowel syndrome (IBS) is a complex condition that involves problems with bowel movements and belly pain, bloating, and gas. It is not life threatening, but can be a longlasting problem that changes life quality. Several studies have shown that up to 70–90% of patients with IBS who seek treatment have psychiatric co-morbidity, most notably mood and anxiety disorders. There are different approaches in the medication for IBS. Antidepressants such as tricyclic antidepressants and selective serotonin reuptake inhibitors are shown to be useful in the treatment. Vortioxetine may become a possible new agent in the treatment of patients with major depressive disorder and IBS with diarrhoea co-morbidity

EISSN 2475-0581